Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation
Status
Conditions
Treatments
Details and patient eligibility
About
Currently, there is very little research to identify ways to decrease blood loss during D&E (dilation and evacuation) procedures. The objective is to determine whether routine use of intravenous oxytocin will improve bleeding outcomes at the time of D&E at 18-24-weeks gestation. To evaluate the hypothesis, investigators will perform a randomized, double-blinded, placebo-controlled trial. The patient will be followed until discharged from the postoperative care unit during which time patient satisfaction, pain score and postoperative bleeding will be assessed.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Requesting pregnancy termination
- Intrauterine pregnancy at 18- to 24-weeks gestation
- Gestational-age to be confirmed by ultrasound
- Patients with fetal anomaly or intrauterine fetal demise that occurred at 18- to 24-weeks gestation
- Willing and able to understand and sign written informed consents in English or Spanish and comply with study procedures
Exclusion criteria
- Ultrasound findings suggestive of placenta accreta
- Patients requiring preoperative misoprostol
Trial design
Primary purpose
Allocation
Interventional model
Masking
166 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal